

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is filed in accordance with the duty of disclosure under 37 CFR §1.56 and §§1.97-1.98, as supplemented by M.P.E.P. §609. Presentation of documents listed on enclosed Form PTO-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 CFR §1.131 or otherwise.

Documents AD, AE, BC and BD identified on enclosed Form PTO-1449 were cited in a Supplementary Partial European Search Report dated June 22, 2001, in a counterpart application in the European Patent Office, as being Category A references relating to technological background. A copy of that Search Report is also enclosed herewith for the Examiner's convenience.

Documents AC, AF-AI and CD-CY were cited in opposition papers filed in a counterpart application in the patent office of Turkey.

Documents CG, CK, CL, CN, CO and CQ are in the Turkish language and no English translation is available. Applicant believes their relevance, if any, to the present Application is as technological background only, as characterized more fully below. None of these documents is believed to contain any reference to celecoxib or other selective COX-2 inhibitory drugs.

Document CG (Ayanoglu, 1981) is cited by an opponent as disclosing examples allegedly showing that micronization of a drug leads to an increase in its dissolution rate and bioavailability.

Documents CK (Geçgil, 1991), CL (Güven, 1979), CN (Igzü, date unknown) and CO (Igzü, 1983) are cited by opponents as allegedly disclosing well known methods and/or excipient ingredients for tablet and capsule preparation.

Document CQ (Kayaalp, date unknown) appears to comprise two sections from a textbook of medicinal pharmacology. The section at Vol. 1, pp. 27-28 is included in a citation list submitted by an opponent but is not referenced elsewhere in the opponent's submission, therefore Applicant cannot determine whether it has any relevance to the present Application. The section at Vol. 2, p. 1050 is cited by an opponent as disclosing therapeutic doses and forms allegedly relevant to Claims 7-12.